Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4619-4629

  Veytsman, Irina ^a   Nieman, Lynnette ^a   Fojo, Tito ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; APREPITANT; BUDESONIDE; CYCLOSPORIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOMIDATE; ETOPOSIDE; FELODIPINE; FENTANYL; FLUTICASONE; GEFITINIB; HYDROCORTISONE; IRINOTECAN; KETOCONAZOLE; LAPATINIB; METHYLPREDNISOLONE; METYRAPONE; MIDAZOLAM; MITOTANE; PARACETAMOL; SIMVASTATIN; SPIRONOLACTONE; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VINCRISTINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACNE; ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ANTIFUNGAL ACTIVITY; ANTIHYPERTENSIVE THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BILIRUBIN BLOOD LEVEL; BONE MARROW DEPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CASE CONTROL STUDY; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTACT DERMATITIS; CUSHING SYNDROME; DEEP VEIN THROMBOSIS; DIARRHEA; DISTANT METASTASIS; DIZZINESS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ERYTHEMA MULTIFORME; FEMINIZATION; FEVER; GYNECOMASTIA; HEADACHE; HEPATITIS A; HIGH RISK PATIENT; HIRSUTISM; HORMONE SYNTHESIS; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPNOSIS; HYPOKALEMIA; HYPOTENSION; HYPOTHYROIDISM; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MORNING DOSAGE; MYOCLONUS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; RASH; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPEECH DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; VERTIGO; VIRILIZATION; VOMITING; WEAKNESS;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADRENOCORTICAL HYPERFUNCTION; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; MALE; MITOTANE;

EID: 76749114385     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.2775     Document Type: Review

References (120)

1. Vaughan ED Jr: Diseases of the adrenal gland. Med Clin North Am 88:443-466, 2004
2. Roman S: Adrenocortical carcinoma. Curr Opin Oncol 18:36-42, 2006
3. Dackiw AP, Lee JE, Gagel RF, et al: Adrenal cortical carcinoma. World J Surg 25:914-926, 2001
4. Icard P, Goudet P, Charpenay C, et al: Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891-897, 2001
5. Plager JE: Carcinoma of the adrenal cortex: Clinical description, diagnosis, and treatment. Int Adv Surg Oncol 7:329-353, 1984
6. Kebebew E, Reiff E, Duh QY, et al: Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World J Surg 30:872-878, 2006
7. Nieman LK, Biller BM, Findling JW, et al: The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526-1540, 2008
8. Derksen J, Nagesser SK, Meinders AE, et al: Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 331:968-973, 1994
9. Wang FF, Chang YH, Pan CC, et al: Unusual visualization of an adrenal carcinoma on NP-59 scintiscan. J Formos Med Assoc 105:340-345, 2006
10. Latronico AC, Chrousos GP: Neoplasms of the adrenal cortex: Clinical and basic aspects. Cancer Treat Res 89:217-237, 1997
11. Luton JP, Cerdas S, Billaud L, et al: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195-1201, 1990
12. Lüscher T, Tenschert W, Salvetti A, et al: Primary aldosteronism due to adrenal carcinomas. Klin Wochenschr 62:470-477, 1984
13. Seccia TM, Fassina A, Nussdorfer GG, et al: Aldosterone-producing adrenocortical carcinoma: An unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 12: 149-159, 2005
14. Foye LV Jr, Feichtmeir TV: Adrenal cortical carcinoma producing solely mineralocorticoid effect. Am J Med 19:966-975, 1955
15. Funder JW, Carey RM, Fardella C, et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266-3281, 2008
16. Nussey S, Whitehead SA: Endocrinology: An Integrated Approach. Oxford, United Kingdom, Bios, 2001, pp xi, 358
17. Mantero F, Terzolo M, Arnaldi G, et al: A survey on adrenal incidentaloma in Italy: Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637-644, 2000
18. Berruti A, Terzolo M, Sperone P, et al: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial. Endocr Relat Cancer 12:657-666, 2005
19. Favia G, Lumachi F, D'Amico DF: Adrenocortical carcinoma: Is prognosis different in nonfunctioning tumors? Results of surgical treatment in 31 patients. World J Surg 25:735-738, 2001
20. Abiven G, Coste J, Groussin L, et al: Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91:2650-2655, 2006
21. Terzolo M, Angeli A, Fassnacht M, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372-2380, 2007
22. Korobkin M, Brodeur FJ, Yutzy GG, et al: Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. Am J Roentgenol 166:531-536, 1996
23. Mitchell DG, Crovello M, Matteucci T, et al: Benign adrenocortical masses: Diagnosis with chemical shift MR imaging. Radiology 185:345-351, 1992
24. Outwater EK, Siegelman ES, Huang AB, et al: Adrenal masses: Correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 200:749-752, 1996
25. Goldfarb DA, Novick AC, Lorig R, et al: Magnetic resonance imaging for assessment of vena caval tumor thrombi: A comparative study with venacavography and computerized tomography scanning. J Urol 144:1100-1103, 1990; discussion 1103-1104
26. Mackie GC, Shulkin BL, Ribeiro RC, et al: Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 91:2665-2671, 2006
27. Leboulleux S, Dromain C, Bonniaud G, et al: Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: A prospective comparison with computed tomography. J Clin Endocrinol Metab 91:920-925, 2006
28. Ahmed M, Al-Sugair A, Alarifi A, et al: Wholebody positron emission tomographic scanning in patients with adrenal cortical carcinoma: Comparison with conventional imaging procedures. Clin Nucl Med 28:494-497, 2003
29. Shulkin BL, Thompson NW, Shapiro B, et al: Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212:35-41, 1999
30. Weiss LM: Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169, 1984
31. Gicquel C, Bertagna X, Gaston V, et al: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767, 2001
32. Aubert S, Wacrenier A, Leroy X, et al: Weiss system revisited: A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 26:1612-1619, 2002
33. Henley DJ, van Heerden JA, Grant CS, et al: Adrenal cortical carcinoma: A continuing challenge. Surgery 94:926-931, 1983
34. Pommier RF, Brennan MF: An eleven-year experience with adrenocortical carcinoma. Surgery 112:963-970, 1992; discussion 970-971
35. Assié G, Antoni G, Tissier F, et al: Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92:148-154, 2007
36. Bellantone R, Ferrante A, Boscherini M, et al: Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 122:1212-1218, 1997
37. Hutter AM Jr, Kayhoe DE: Adrenal cortical carcinoma: Clinical features of 138 patients. Am J Med 41:572-580, 1966
38. Markoe AM, Serber W, Micaily B, et al: Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 14:170-174, 1991
39. Fassnacht M, Hahner S, Polat B, et al: Effi-cacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501-4504, 2006
40. Berruti A, Terzolo M, Pia A, et al: Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma: Italian Group for the Study of Adrenal Cancer. Cancer 83:2194-2200, 1998
41. Berruti A, Sperone P, Daffara PS, et al: Adjuvant mitotane therapy for adreno-cortical carcinoma. J Clin Oncol 23:395s, 2005 (suppl; abstr 4570)
42. Bukowski RM, Wolfe M, Levine HS, et al: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study. J Clin Oncol 11:161-165, 1993
43. Schlumberger M, Brugieres L, Gicquel C, et al: 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67: 2997-3000, 1991
44. Abraham J, Bakke S, Rutt A, et al: A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94:2333-2343, 2002
45. Williamson SK, Lew D, Miller GJ, et al: Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group Study. Cancer 88:1159-1165, 2000
46. Bonacci R, Gigliotti A, Baudin E, et al: Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma: Reseau Comete INSERM. Br J Cancer 78:546-549, 1998
47. Khan TS, Imam H, Juhlin C, et al: Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use. Ann Oncol 11:1281-1287, 2000
48. Didolkar MS, Bescher RA, Elias EG, et al: Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients. Cancer 47:2153-2161, 1981
49. King DR, Lack EE: Adrenal cortical carcinoma: A clinical and pathologic study of 49 cases. Cancer 44:239-244, 1979
50. Trainer PJ, Besser M: Cushing's syndrome. Therapy directed at the adrenal glands. Endocrinol Metab Clin North Am 23:571-584, 1994
51. Young RB, Bryson MJ, Sweat ML, et al: Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem 4:585-591, 1973
52. Schteingart DE: Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res 33:1197-1200, 2000
53. Piñeiro-Sánchez ML, Vaz ADN, Counsell RE, et al: Synthesis of ß3H-mitotane for use in a rapid assay for mitotane metabolism. J Label Comp Radiopharmaceut 36:121-127, 1995
54. Moy RH: Studies of the pharmacology of o,p'DDD in man. J Lab Clin Med 58:296-304, 1961
55. Cueto C, Brown JH, Richardson AP Jr: Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology 62:334-339, 1958
56. Moolenaar AJ, van Slooten H, van Seters AP, et al: Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol 7:51-54, 1981
57. Baudin E, Pellegriti G, Bonnay M, et al: Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385-1392, 2001
58. van Slooten H, Moolenaar AJ, van Seters AP, et al: The treatment of adrenocortical carcinoma with o,p'-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47-53, 1984
59. Terzolo M, Pia A, Berruti A, et al: Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 85:2234-2238, 2000
60. Heilmann P, Wagner P, Nawroth PP, et al: Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels [in German]. Med Klin (Munich) 96:371-377, 2001
61. Maher VM, Trainer PJ, Scoppola A, et al: Possible mechanism and treatment of o,p'DDDinduced hypercholesterolaemia. Q J Med 84:671-679, 1992
62. Hague RV, May W, Cullen DR: Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf) 31:51-57, 1989
63. Cuddy PG, Loftus LS: Influence of mitotane on the hypoprothrombinemic effect of warfarin. South Med J 79:387-388, 1986
64. Hahner S, Fassnacht M: Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6:386-394, 2005
65. Graybill JR, Drutz DJ, Murphy AL: Ketoconazole: A major innovation for treatment of fungal disease. Ann Intern Med 93:921-923, 1980
66. DeFelice R, Johnson DG, Galgiani JN: Gynecomastia with ketoconazole. Antimicrob Agents Chemother 19:1073-1074, 1981
67. Buttke TM, Chapman SW: Inhibition by ketoconazole of mitogen-induced DNA synthesis and cholesterol biosynthesis in lymphocytes. Antimicrob Agents Chemother 24:478-485, 1983
68. Santen RJ, Van den Bossche H, Symoens J, et al: Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 57:732-736, 1983
69. Engelhardt D, Dörr G, Jaspers C, et al: Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klin Wochenschr 63: 607-612, 1985
70. Nagai K, Miyamori I, Ikeda M, et al: Effect of ketoconazole (an imidazole antimycotic agent) and other inhibitors of steroidogenesis on cytochrome P450-catalyzed reactions. J Steroid Biochem 24: 321-323, 1986
71. Loose DS, Stover EP, Feldman D: Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest 72:404-408, 1983
72. Sonino N: The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317: 812-818, 1987
73. Lewis JH, Zimmerman HJ, Benson GD, et al: Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases. Gastroenterology 86:503-513, 1984
74. McCance DR, Ritchie CM, Sheridan B, et al: Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1: 573, 1987
75. Sugar AM, Alsip SG, Galgiani JN, et al: Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 31:1874-1878, 1987
76. Aabo K, De Coster R: Hypertension during high-dose ketoconazole treatment: A probable mineralocorticosteroid effect. Lancet 2:637-638, 1987
77. Ross JB, Levine B, Catanzaro A, et al: Ketoconazole for treatment of chronic pulmonary coccidioidomycosis. Ann Intern Med 96:440-443, 1982
78. Sella A, Kilbourn R, Amato R, et al: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12:683-688, 1994
79. Pont A, Williams PL, Loose DS, et al: Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 97:370-372, 1982
80. Pont A, Williams PL, Azhar S, et al: Ketoconazole blocks testosterone synthesis. Arch Intern Med 142:2137-2140, 1982
81. Rollman O, Jameson S, Lithell H: Effects of long-term ketoconazole therapy on serum lipid levels. Eur J Clin Pharmacol 29:241-245, 1985
82. Kitching NH: Hypothyroidism after treatment with ketoconazole. BMJ (Clin Res Ed) 293:993-994, 1986
83. Millikan R, Baez L, Banerjee T, et al: Randomized phase 2 trial of ketoconazole and ketoconazole/ doxorubicin in androgen independent prostate cancer. Urol Oncol 6:111-115, 2001
84. Eklund J, Kozloff M, Vlamakis J, et al: Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer 106: 2459-2465, 2006
85. Oh WK, Hagmann E, Manola J, et al: A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormonerefractory prostate cancer. Clin Cancer Res 11:284-289, 2005
86. Liddle GW, Estep HL, Kendall JW Jr, et al: Clinical application of a new test of pituitary reserve. J Clin Endocrinol Metab 19:875-894, 1959
87. Newell-Price J, Trainer P, Besser M, et al: The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19:647-672, 1998
88. Beardwell CG, Adamson AR, Shalet SM: Prolonged remission in florid Cushing's syndrome following metyrapone treatment. Clin Endocrinol (Oxf) 14:485-492, 1981
89. Child DF, Burke CW, Burley DM, et al: Drug controlled of Cushing's syndrome: Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh) 82:330-341, 1976
90. Thoren M, Adamson U, Sjoberg HE: Aminoglutethimide and metyrapone in the management of Cushing's syndrome. Acta Endocrinol (Copenh) 109:451-457, 1985
91. Carballeira A, Fishman LM, Jacobi JD: Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: Correlation of in vivo and in vitro studies. J Clin Endocrinol Metab 42:687-695, 1976
92. Sonino N, Chow D, Levine LS, et al: Clinical response to metyrapone as indicated by measurement of mineralocorticoids and glucocorticoids in normal children. Clin Endocrinol (Oxf) 14:31-39, 1981
93. Haynes RC: Adrenocorticotropic hormone: Adrenocortical steroids and their synthetic analogs-Inhibitors of the synthesis and actions of adrenocortical hormones, in Gilman AG, Rall TW, Nies AS, et al (eds): The Pharmacological Basis of Therapeutics (ed 8). New York, NY, Pergamon Press, 1990, pp 1431-1462
94. Verhelst JA, et al: Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 35:169-178, 1991
95. Nieman LK: Medical therapy of Cushing's disease. Pituitary 5:77-82, 2002
96. Schimmer BP, Parker KL:. Chapter 59: Adrenocorticotrophic hormone: Adrenocortical steroids and their synthetic analogs: Inhibitors of the synthesis and actions of adrenocortical hormones, in Hardman JG, Limbird LE, Molinoff PB, et al (eds): The Pharmacological Basis of Therapeutics (ed 9). New York, NY, McGraw-Hill, 1996, pp 1459-1486
97. Nieman LK: Medical therapy of Cushing's disease. Pituitary 5:77-82, 2002
98. Dickstein G, Lahav M, Shen-Orr Z, et al: Primary therapy for Cushing's disease with metyrapone. JAMA 255:1167-1169, 1986
99. Galinsky RE, Nelson EB, Rollins DE: Pharmacokinetic consequences and toxicologic implications of metyrapone-induced alterations of acetaminophen elimination in man. Eur J Clin Pharmacol 33:391-396, 1987
100. Watt I, Ledingham IM: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 39:973-981, 1984
101. Wagner RL, White PF, Kan PB, et al: Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 310:1415-1421, 1984
102. Lamberts SW, Bons EG, Bruining HA, et al: Differential effects of the imidazole derivatives etomidate, ketoconazole, and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 240:259-264, 1987
103. Allolio B, Dörr H, Stuttmann R, et al: Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. Clin Endocrinol (Oxf) 22:281-286, 1985
104. Johnson TN, Canada TW: Etomidate use for Cushing's syndrome caused by an ectopic adrenocorticotropic hormone-producing tumor. Ann Pharmacother 41:350-353, 2007
105. Schulte HM, Benker G, Reinwein D, et al: Infusion of low dose etomidate: Correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70:1426-1430, 1990
106. Allolio B, Schulte HM, Kaulen D, et al: Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr 66:361-364, 1988
107. Krakoff J, Koch CA, Calis KA, et al: Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 86:4104-4108, 2001
108. Moore CA, Hamilton SF, Underhill AL, et al: Potentiation of etomidate anesthesia by verapamil: A report of two cases. Hosp Pharm 24:24-25, 1989
109. Bergenstal DM, Hertz R, Lipsett MB, et al: Chemotherapy of adrenocortical cancer with o,p' DDD. Ann Intern Med 53:672-682, 1960
110. Hutter AMJ, Kayhoe DE: Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med 41:581-592, 1966
111. Lubitz JA, Freeman L, Okun R: Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223: 1109-1112, 1973
112. Venkatesh S, Hickey RC, Sellin RV, et al: Adrenal cortical carcinoma. Cancer 64:765-769, 1989
113. Decker RA, Elson P, Hogan TF, et al: Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110:1006-1013, 1991
114. Haak HR, Hermans J, van de Velde CJ, et al: Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 69:947-951, 1994
115. Barzon L, Fallo F, Sonino N, et al: Adrenocortical carcinoma: Experience in 45 patients. Oncology 54:490-496, 1997
116. Hoffman DL, Mattox VR: Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin North Am 56:999-1012, 1972
117. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al: Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71:3119-3123, 1993
118. Dickstein G, Shechner C, Nativ O: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 357:1257-1258, 2007; author reply 1259
119. Schteingart DE, Motazedi A, Noonan RA, et al: Treatment of adrenal carcinomas. Arch Surg 117:1142-1146, 1982
120. Bertherat J, Coste J, and Bertagna X: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med 357:1256-1257, 2007; author reply 1259